Piclozotan

Drug Profile

Piclozotan

Alternative Names: SUN 4057; SUN N 4057

Latest Information Update: 13 May 2014

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Asubio Pharma
  • Class Anti-ischaemics; Neuroprotectants; Oxazepines; Small molecules
  • Mechanism of Action Serotonin 1A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Dyskinesias
  • Discontinued Stroke

Most Recent Events

  • 13 May 2014 No development reported - Phase-II for Dyskinesia in USA, Guatemala & Romania (IV)
  • 11 Jun 2009 Pharmacodynamics data from a preclinical trial in Parkinson's disease presented at the 13th International Congress of Parkinson's Disease and Movement Disorders (PDMD-2009)
  • 15 Jul 2008 Discontinued - Phase-II for Stroke in European Union (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top